Pancryos has obtained a worldwide exclusive license agreement Cooperation between Brigham Hospital and Women’s Hospital for convection-enhanced macroencapsulation device (ceMED).
Harvard Stem Cell Research Institute Brigham Hospital and Women’s Hospital Researcher Team (HSCI), Harvard University, University of Massachusetts School of Medicine have developed ceMED.
The device acts as a delivery mechanism for PanINSULA, the company’s stem cell-derived natural insulin-producing therapy for the treatment of type 1 diabetes.
It aims to increase cell load capacity while increasing cell survival, glucose sensitivity, and timely secretion of insulin.
This device has been shown to promote cell survival and insulin secretion in preclinical models and began to lower blood glucose levels 2 days after transplantation.
Compared to current diffusion-based devices, ceMED offers significant benefits such as improved cell viability, reduced fibrous encapsulation, and faster on / off rates of insulin secretion.
According to the first findings made with the ceMED device, its unique design may overcome the mass transfer limitations of standard macroencapsulation devices without affecting cell viability or function. , May facilitate delivery of higher doses to cells.
Henrik Semb, co-founder of Pancryos, said:
“This exclusive license puts Pancryos in a unique position to provide high-quality beta cells with innovative ceMED devices that protect cells from immune attacks.
“This is a very exciting development for the treatment of type 1 diabetes and the treatment of millions of people suffering without cure.”
There is no known cure for type 1 diabetes, affecting more than 50 million people worldwide.